Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › idarucizumab

idarucizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of idarucizumab

6 trials tracked of idarucizumab: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 1456 citations.

6Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 4 Phase 1 2
  1. Phase 3 Reversal of Dabigatran Anticoagulant Effect With Idarucizumab Completed · 1,456 cited
  2. Phase 3 Reversal Dabigatran Anticoagulant Effect With Idarucizumab Completed · 15 cited
  3. Phase 3 CU Programme of Idarucizumab for Japanese Patients Completed
  4. Phase 3 This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding Completed
  5. Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects Completed
  6. Phase 1 Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Specific reversal agents offer high-affinity neutralization but face cost and access barriers in thromboembolism management
Cardiology Sys. Review
Specific reversal agents offer high-affinity neutralization but face cost and access barriers in thromboembolism management New Options and Challenges for Reversing Blood Clot Treatments
This systematic review evaluates procoagulant strategies including specific reversal agents like idarucizumab and non-specific options for t…
Doctors are evaluating specific and non-specific agents to safely reverse the effects of anticoagulant medications in patients with blood cl…
Frontiers Jun 25, 2026
Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation
Cardiology Meta-analysis
Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation Reversing blood thinners may allow stroke treatment with good safety and recovery
This meta-analysis and case report review examines idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with peripro…
Reversing dabigatran before stroke treatment appears safe, showing low bleeding and death rates with recovery similar to standard care.
Frontiers Apr 22, 2026